340 related articles for article (PubMed ID: 37298373)
1. Targeting IGF2BP3 in Cancer.
Liu X; Chen J; Chen W; Xu Y; Shen Y; Xu X
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298373
[TBL] [Abstract][Full Text] [Related]
2. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
[TBL] [Abstract][Full Text] [Related]
3. The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability.
Zhang N; Shen Y; Li H; Chen Y; Zhang P; Lou S; Deng J
Exp Mol Med; 2022 Feb; 54(2):194-205. PubMed ID: 35217832
[TBL] [Abstract][Full Text] [Related]
4. Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.
Wu T; Zhang X; Xing L; Pan D; Liu P; Ding R; Yang R; Yang X; Li Y
Dis Markers; 2022; 2022():5883101. PubMed ID: 35677634
[TBL] [Abstract][Full Text] [Related]
5. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
[TBL] [Abstract][Full Text] [Related]
6. IGF2BP3 is an essential N
Xu X; Cui J; Wang H; Ma L; Zhang X; Guo W; Xue X; Wang Y; Qiu S; Tian X; Miao Y; Wu M; Yu Y; Xu Y; Wang J; Qiao Y
Mater Today Bio; 2022 Dec; 17():100503. PubMed ID: 36457846
[TBL] [Abstract][Full Text] [Related]
7. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
[TBL] [Abstract][Full Text] [Related]
8. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
Fan J; Zhuang M; Fan W; Hou M
PeerJ; 2023; 11():e15706. PubMed ID: 37663284
[TBL] [Abstract][Full Text] [Related]
9. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma.
Du M; Peng Y; Li Y; Sun W; Zhu H; Wu J; Zong D; Wu L; He X
Cell Death Discov; 2022 Feb; 8(1):53. PubMed ID: 35136045
[TBL] [Abstract][Full Text] [Related]
10. Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1.
Yang Z; Zhao F; Gu X; Feng L; Xu M; Li T; Liu X; Zhang X
Am J Cancer Res; 2021; 11(4):1428-1445. PubMed ID: 33948366
[TBL] [Abstract][Full Text] [Related]
11. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.
Zhu K; Gao T; Wang Z; Zhang L; Tan K; Lv Z
Cell Death Discov; 2023 May; 9(1):151. PubMed ID: 37156775
[TBL] [Abstract][Full Text] [Related]
12. IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization.
Qin J; Cui Z; Zhou J; Zhang B; Lu R; Ding Y; Hu H; Cai J
Transl Oncol; 2023 Nov; 37():101764. PubMed ID: 37643553
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact of
Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Ji G; Huang C; He S; Gong Y; Song G; Li X; Zhou L
Aging (Albany NY); 2020 Jul; 12(14):14863-14884. PubMed ID: 32710725
[TBL] [Abstract][Full Text] [Related]
15. IGF2BP3/HIF1A/YAP signaling plays a role in driving acute-on-chronic liver failure through activating hepatocyte reprogramming.
Cheng K; Liu S; Li C; Zhao Y; Wang Q
Cell Signal; 2023 Aug; 108():110727. PubMed ID: 37257765
[TBL] [Abstract][Full Text] [Related]
16. circRNA N6-methyladenosine methylation in preeclampsia and the potential role of N6-methyladenosine-modified circPAPPA2 in trophoblast invasion.
Zhang Y; Yang H; Long Y; Zhang Y; Chen R; Shi J; Chen J
Sci Rep; 2021 Dec; 11(1):24357. PubMed ID: 34934095
[TBL] [Abstract][Full Text] [Related]
17. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
19. The role of m6A RNA methylation in cancer.
Sun T; Wu R; Ming L
Biomed Pharmacother; 2019 Apr; 112():108613. PubMed ID: 30784918
[TBL] [Abstract][Full Text] [Related]
20. RNA m6A reader IGF2BP3 promotes metastasis of triple-negative breast cancer via SLIT2 repression.
Jiang T; He X; Zhao Z; Zhang X; Wang T; Jia L
FASEB J; 2022 Nov; 36(11):e22618. PubMed ID: 36250924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
